Lodoxamide in vernal keratoconjunctivitis

Annals of Pharmacotherapy

Volumn 30, Issue 5, 1996, Pages 535-537

  Lee, Sally ^a   Allard, Teresa Rfk ^b,c  

^a KAISER PERMANENTE   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LODOXAMIDE;

ADOLESCENT; ALLERGIC REACTION; ARTICLE; CHILD; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; KERATOCONJUNCTIVITIS; MAJOR CLINICAL STUDY; MALE; MAST CELL; NAUSEA; PAIN; PRIORITY JOURNAL; PRURITUS; TOPICAL DRUG ADMINISTRATION; VERNAL CONJUNCTIVITIS;

EID: 0029874070     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000519     Document Type: Article

References (19)

1. Caldwell DR, Verin P, Haitwich-Young R, Meyer SM, Drake MM. Efficacy and safety of lodoxamide 0.1% vs. cromolyn sodium 4% in patients with vernal keratoconjunctivitis. Am J Ophthalmol 1992;113:632-7.
2. Diseases of the conjunctiva. In: Sanford-Smith J, ed. Eye diseases in hot climates, 2nd ed. London: Wright, 1990:70-2.
3. Vaughan D, Ashbury T, Riordan-Eva P, eds. General ophthalmology. Norwalk, CT: Appleton and Lange, 1992:111-2.
4. Fahy GT, Easty DL, Collum LMT, Benedict-Smith A, Hillery M, Parsons DG. Randomized double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicenter study. Eur J Ophthalmol 1992;2:144-9.
5. Santos CI, Huang AJ, Abelson MB, Foster CS, Friedlaender M, McCulley JP. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am J Ophthalmol 1994;117:488-97.
6. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992;10:505-12.
7. Holland EJ, Oben TW, Ketcham JM, Florine C, Krachmer JH, Purcell JJ, et al. Topical cyclosporine A in the treatment of anterior segment inflammatory disease. Cornea 1993;12:413-9.
8. Abramowitz M, ed. Ophthalmic levocabastine for allergic conjunctivitis. Med Lett 1994;36:35-7.
9. Abelson MB, Sloan J Nonsteroidal anti-inflammatory drugs Current ophthalmic therapy. J Fla Med Assoc 1994;81:261-3
10. Tinkelman DG, Rupp G, Kaufman H, Pugely J, Schnitz N. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared to placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38 (suppl):133-40
11. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38 (suppl) 141-8.
12. Newell FW. Ophthalmology principles and concepts. 5th ed. St. Louis: CV Mosby, 1982:193.
13. Kaan G, Ozden O Therapeutic use of topical cyclosporine. Ann Ophthalmol 1993;25:182-6.
14. Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991;98:1679-84.
15. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990;110:641-5.
16. Garret HM, ed. Drug topics redbook update. Medical Economics, 1995.
17. Johnson HG, Van Hout CA, Wright JB. Inhibition of allergic reactions by cromoglycate and by a new anti-allergy drug U-42,585E. Int Arch Allergy Appl Immunol 1978;56:416-23
18. The pink sheet. Alcon Labs Atomide (lodoxamide tromethamine 0.1%) approved Sept 23. FDC Rep 1993;Oct 4:T&G-2.
19. Johnson HG, Griffin RL, Wright JB The effect of lodoxamide ethyl [diethyl N, N′-(2-chloro-5-cyano-m-phenylene) dioxamate] on in vivo anaphylactic reactions. Agents Actions 1979;9:235-8.